Literature DB >> 32304165

Restriction of eye motility in patients with RETINA IMPLANT Alpha AMS.

Hanna Faber1, Dorothea Besch1, Karl-Ulrich Bartz-Schmidt1, Hanna Eisenstein1, Johann Roider2, Helmut Sachs3, Florian Gekeler4, Eberhart Zrenner5,6, Katarina Stingl1,7.   

Abstract

PURPOSE: To evaluate the motility of the eye in patients with the RETINA IMPLANT Alpha AMS.
METHODS: Eye motility was determined in eight gaze directions in ten blind retinitis pigmentosa patients, who had received the RETINA IMPLANT Alpha AMS, before implantation of the subretinal implant and at six time-points up to one year after.
RESULTS: The analysis of eye motility showed a restriction in the upgaze and gaze to the temporal side directly after surgery in eight of the nine patients included. The degree of motility restriction decreased continuously with recovery during the observation time. One year after surgery, eye motility was still restricted in the majority of patients, especially in the upgaze to the temporal side at 20° (five of seven patients).
CONCLUSION: Retinal implants with intraorbital parts (e.g. connecting cables) caused restriction in the temporal and superior viewing directions in the majority of patients. Although this restriction might be cosmetically visible, this limitation in eye motility has no effects on the monocular vision and the implant's efficacy for daily use.
© 2020 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.

Entities:  

Keywords:  eye motility; orbital surgery; retinal prosthesis inherited retinal degenerations; retinitis pigmentosa

Year:  2020        PMID: 32304165     DOI: 10.1111/aos.14435

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  1 in total

Review 1.  Retinal Organoids and Retinal Prostheses: An Overview.

Authors:  Alessandro Bellapianta; Ana Cetkovic; Matthias Bolz; Ahmad Salti
Journal:  Int J Mol Sci       Date:  2022-03-08       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.